(MedPage Today) — Last week marked the FDA’s deadline for compounders to stop making the obesity drug tirzepatide (Zepbound), leaving some patients unsure where to turn next. (NPR)
Dexcom’s investigational 15-day G7 integrated continuous glucose…
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/114813
Author :
Publish date : 2025-03-25 17:13:00
Copyright for syndicated content belongs to the linked Source.
